	US 11,850,243 B2
	Dihydropyridine compositions and methods for treating neurological disorders
Jack Nguyen, Berkeley, CA (US); and Dalton James Surmeier, Jr., Chicago, IL (US)
Assigned to Northwestern University, Evanston, IL (US); and Cavalon Therapeutics, Inc., Berkeley, CA (US)
Filed by Cavalon Therapeutics, Inc., Berkeley, CA (US); and Northwestern University, Evanston, IL (US)
Filed on Jan. 12, 2022, as Appl. No. 17/574,272.
Claims priority of provisional application 63/136,845, filed on Jan. 13, 2021.
Prior Publication US 2022/0241262 A1, Aug. 4, 2022
Int. Cl. A61K 31/4439 (2006.01); A61P 25/16 (2006.01)

CPC A61K 31/4439 (2013.01) [A61P 25/16 (2018.01)]

23 Claims

1. A method of slowing progression of Parkinson's disease in a patient comprising:

(i) administering to said patient a pharmaceutical composition,

wherein said pharmaceutical composition comprises isradipine,

wherein the daily dose of isradipine for said patient is 3 mg to 15 mg,

wherein administration of said pharmaceutical composition to a patient provides a mean plasma profile for isradipine at steady state characterized by a Css of 1.5 to 3.5 ng/ml for not less than 12 hours over a 24 hour period; and

(ii) monitoring the steady state plasma concentration of isradipine in the patients for a period of at least four weeks.